COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,878 Articles (22,568 medRxiv, 8,310 bioRxiv)

Most recent first Previous |  Page 1665: Articles 16641-16650  | Next

Common dandelion (Taraxacum officinale) efficiently blocks the interaction between ACE2 cell surface receptor and SARS-CoV-2 spike protein D614, mutants D614G, N501Y, K417N and E484K in vitro
Tran, H. T. T., Le, N. P. K., Gigl, M., Dawid, C., Lamy, E.
10.1101/2021.03.19.435959 — Posted: 2021-03-19
The inhibitory effects of toothpaste and mouthwash ingredients on the interaction between the SARS-CoV-2 spike protein and ACE2, and the protease activity of TMPRSS2, in vitro
Tateyama-Makino, R., Abe-Yutori, M., Iwamoto, T., Tsutsumi, K., Tsuji, M., Morishita, S., Kurita, K., Yamamoto, Y., Nishinaga, E., Tsukinoki, K.
10.1101/2021.03.19.435740 — Posted: 2021-03-19
Combined computational and cellular screening identifies synergistic inhibition of SARS-CoV-2 by lenvatinib and remdesivir
Pohl, M. O., Busnadiego, I., Marrafino, F., Wiedmer, L., Hunziker, A., Fernbach, S., Omori, E., Hale, B. G., Caflisch, A., Silke, S.
10.1101/2021.03.19.435806 — Posted: 2021-03-19
Reduced neutralization of SARS-CoV-2 variants by convalescent plasma and hyperimmune intravenous immunoglobulins for treatment of COVID-19
Tang, J., Lee, Y., Ravichandran, S., Grubbs, G., Huang, C., Stauft, C., Wang, T., Golding, B., Golding, H., Khurana, S.
10.1101/2021.03.19.436183 — Posted: 2021-03-19
Dendritic cell deficiencies persist seven months after SARS-CoV-2 infection
Perez-Gomez, A., Vitalle, J., Gasca-Capote, M. d. C., Gutierrez-Valencia, A., Trujillo-Rodriguez, M., Serna-Gallego, A., Munoz-Muela, E., Jimenez-Leon, M. d. l. R., Rafii-El-Idrissi Benhnia, M., Rivas-Jeremias, I., Sotomayor, C., Roca-Oporto, C., Espinosa, N., Infante-Dominguez, C., Crespo-Rivas, J. C., Fernandez-Villar, A., Perez-Gonzalez, A., Lopez-Cortes, L. F., Poveda, E., Ruiz-Mateos, E.
10.1101/2021.03.18.436001 — Posted: 2021-03-19
A combined strategy to detect plasma samples reliably with high anti-SARS-CoV-2 neutralizing antibody titers in routine laboratories
Fischer, B., Lichtenberg, C., Mueller, L., Timm, J., Fischer, J., Knabbe, C.
10.1101/2021.03.15.21253588 — Posted: 2021-03-19
The B1.351 and P.1 variants extend SARS-CoV-2 host range to mice
Montagutelli, X., Prot, M., Levillayer, L., Baquero Salazar, E., Jouvion, G., Conquet, L., Donati, F., Albert, M., Gambaro, F., Behillil, S., Enouf, V., Rousset, D., Jaubert, J., Rey, F., van der Werf, S., Simon-Loriere, E.
10.1101/2021.03.18.436013 — Posted: 2021-03-18 Discussion: Onsite
Evaluation of a new spike (S) protein based commercial immunoassay for the detection of anti-SARS-CoV-2 IgG
Eberhardt, K. A., Dewald, F., Heger, E., Gieselmann, L., Vanshylla, K., Wirtz, M., Kleipass, F., Johannis, W., Schommers, P., Gruell, H., Brensing, K. A., Mueller, R.-U., Augustin, M., Lehmann, C., Koch, M., Klein, F., Di Cristanziano, V.
10.1101/2021.03.10.21253288 — Posted: 2021-03-18
Genetic variability associated with OAS1 expression in myeloid cells increases the risk of Alzheimer's disease and severe COVID-19 outcomes
Magusali, N., Graham, A. C., Piers, T. M., Panichnantakul, P., Yaman, U., Shoai, M., Reynolds, R. H., Botia, J. A., Brookes, K. J., Guetta-Baranes, T., Bellou, E., Bayram, S., Sokolova, D., Ryten, M., Sala Frigerio, C., Escott-Price, V., Morgan, K., Pocock, J. M., Hardy, J., Salih, D. A.
10.1101/2021.03.16.435702 — Posted: 2021-03-18 Discussion: Onsite
Identification of guanylyltransferase activity in the SARS-CoV-2 RNA polymerase
Walker, A. P., Fan, H., Keown, J. R., Grimes, J., Fodor, E.
10.1101/2021.03.17.435913 — Posted: 2021-03-18

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).